In the era of HER2‐ADC, comprehensive studies including considerable HER2 non‐ex20ins patients were warranted to investigate how HER2 mutation subtype affects ADC efficacy and whether immunotherapy or HER2‐ADC would be the optimal first‐line regimen for NSCLC patients with specific subtypes of HER2 mutations. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.